ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

NRSN vs ENLV // FREE CASH FLOW YIELD

NeuroSense Therapeutics Ltd. (NASDAQ) VS. Enlivex Ltd. (NASDAQ) • 15-METRIC TALLY: NRSN 1 — ENLV 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NRSN VS. ENLV) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC NRSN ENLV SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -0.60% -34.40 ENLV /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield ACTIVE — — — TIE /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 3/9 -2.00 ENLV /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 21.6 65.3 -43.77 ENLV /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $4.0M $3.9M $149.1K NRSN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR NRSN REV ENLV REV NRSN GROSS % ENLV GROSS % NRSN FCF ENLV FCF
FY 2025 $0 $0 — — -$7.7M -$10.5M
FY 2024 $0 $0 — — -$10.1M -$13.1M
FY 2023 $0 $0 — — -$8.4M -$23.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NRSN // BETA —
ENLV // BETA —